Sugi Predict

Sugi Predict / Compounds / SCHEMBL2389780

SCHEMBL2389780

SCHEMBL2389780

COc1cc(-c2ccco2)cc(OC)c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.57
▸ SMN1; SMN2 Q16637 6/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ TP53 P04637 2/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ NFKB2 Q00653 1/20 0.50
▸ RELA Q04206 1/20 0.50
▸ TSHR P16473 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ ADORA2A P29274 3/20 0.47
▸ SMPD3 Q9NY59 1/20 0.45
▸ ALDH1A1 P00352 7/20 0.44
▸ HPGD P15428 6/20 0.44
▸ KDM4E B2RXH2 4/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ LMNA P02545 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17471107 0.85 ERN1 (0.46) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL2388588 0.85 MAPT (0.64) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL2385897 0.84 ERN1 (0.56) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL2389984 0.84 ERN1 (0.56) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL2387255 0.84 ERN1 (0.73) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL2387527 0.84 ERN1 (0.56) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL12330908 0.84 ERN1 (0.56) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL11634342 0.81 MEN1 (0.66) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL28000523 0.80 ERN1 (0.52) ERN1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL2385998 0.79 ALDH1A1 (0.53) ERN1SMN1; SMN2MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2544679-B1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORP (US) 2019-05-15 — — EP disclosed
EP-2544679-B1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORP (US) 2019-05-15 — — EP disclosed
US-10106516-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-10-23 — — US disclosed
US-20180057484-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PDE10 INHIBITOR OMEROS CORP (US) 2018-03-01 — — US disclosed
US-9850238-B2 Optically active PDE10 inhibitor OMEROS CORPORATION (US) 2017-12-26 — — US disclosed
US-20170152238-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-06-01 — — US disclosed
US-20170152238-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-06-01 — — US disclosed
US-20170152238-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-06-01 — — US disclosed
US-9650368-B2 Processes and intermediates for the preparation of a PDE10 inhibitor OMEROS CORPORATION (US) 2017-05-16 — — US disclosed
US-20170096420-A1 OPTICALLY ACTIVE PDE10 INHIBITOR OMEROS CORPORATION 2017-04-06 — — US disclosed
US-20130196994-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2013-08-01 — — US disclosed
EP-2544679-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS Omeros Corporation (US) 2013-01-16 — — EP disclosed
US-8343970-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-01-01 — — US disclosed
US-8343970-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-01-01 — — US disclosed
US-8343970-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-01-01 — — US disclosed
WO-2011112828-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — WO disclosed
WO-2011112828-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — WO disclosed
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — US disclosed
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — US disclosed
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106516-B2 PDE10 inhibitors and related compositions and methods PDE10A, PDE9A, PDE7A ERN1 4401/4885SMN1; SMN2 527/4885MEN1 3291/4885
US-20170096420-A1 OPTICALLY ACTIVE PDE10 INHIBITOR PDE3A, PDE10A, PDE3B ERN1 357/4885SMN1; SMN2 2223/4885MEN1 2829/4885
US-20180057484-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PDE10 INHIBITOR PDE3A, PDE3B, PDE5A ERN1 1353/4885SMN1; SMN2 2121/4885MEN1 2053/4885
US-20130196994-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A ERN1 4401/4885SMN1; SMN2 527/4885MEN1 3291/4885
US-20170152238-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A ERN1 4401/4885SMN1; SMN2 527/4885MEN1 3291/4885
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A ERN1 4401/4885SMN1; SMN2 527/4885MEN1 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.